This report presents the findings of the study conducted under the title ‘Disclosure and Compliance of IAS 16 in DSE listed Pharmaceuticals Companies in Bangladesh’. A comprehensive checklist based on IAS 16 was built. In addition to that, the annual reports of the DSE listed Pharmaceutical companies were examined in order to cross-check against the checklist. After that, some statistical measures were taken to yield the overall compliance composition. Some important issues from the checklist were presented graphically. The study shows that in spite of 54% compliance composition score, a significant amount of sample falls under the non-compliance and not applicable condition. However, the study contains a few impediments for which the investigation cannot be generalised for all the DSE listed Pharmaceuticals companies.
